TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12032113

Group type: EXPERIMENTAL
Intervention: Insulin aspart (10 units)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Insulin lispro (10 units)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermediate-acting human insulin (bedtime injection)
Number of subjects: 14
Study: 9835005

Group type: EXPERIMENTAL
Intervention: Bovine pericardium buttressing on stapler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no buttressing)
Number of subjects: 0
Study: 8016794

Group type: EXPERIMENTAL
Intervention: NCPAP treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 2739867

Group type: EXPERIMENTAL
Intervention: Oral VUEFFE (VF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 42
Study: 4596491

Group type: EXPERIMENTAL
Intervention: Monovalent classical Ogawa vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent Inaba vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent El Tor vaccines (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent classical Inaba vaccine
Number of subjects: 0
Study: 31520613

Group type: EXPERIMENTAL
Intervention: Pancolonic chromoendoscopy (n = 128)
Number of subjects: 256

Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (n = 128)
Number of subjects: 256
Study: 30953333

Group type: EXPERIMENTAL
Intervention: roxadustat 50 mg TIW
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: roxadustat 70 mg TIW
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: roxadustat 100 mg TIW
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: roxadustat TIW
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 28726169

Group type: EXPERIMENTAL
Intervention: Clonidine mucoadhesive buccal tablet (MBT) 50 and 100 µg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clonidine mucoadhesive buccal tablet (MBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference clonidine oral tablet (OT)
Number of subjects: 36
Study: 26067732

Group type: EXPERIMENTAL
Intervention: NanoAg‐IS‐BOA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NanoAg‐I‐BOA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control BOA (standard PMMA)
Number of subjects: 24
Study: 23769414

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study: 22090050

Group type: EXPERIMENTAL
Intervention: Vicryl (absorbable sutures)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nylon (nonabsorbable sutures)
Number of subjects: 38
Study: 19339887

Group type: EXPERIMENTAL
Intervention: Recent advancements in RCC treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecularly based biomarker studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical prognostic factors
Number of subjects: 0
Study: 16510545

Group type: COMPARATOR
Intervention: Serum enterolactone concentration (measured by gas chromatography-mass spectrometry)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Highest quintile of serum enterolactone
Number of subjects: 340
Study: 15569790

Group type: EXPERIMENTAL
Intervention: benznidazole
Number of subjects: 0
Study: 11329233

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 5 mg/d for 13 days, for 9 months
Number of subjects: 59
Study: 9416890

Group type: EXPERIMENTAL
Intervention: Pulse pressure measurement (sphygmomanometry)
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Captopril or placebo (treatment arm)
Number of subjects: 2231
Study: 8495311

Group type: EXPERIMENTAL
Intervention: Cefazolin, 500 mg every 8 hours for 24 hours
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 113
Study: 3122113

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified Goeckerman treatment
Number of subjects: 40
Study: 29497290

Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 60

Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 60
Study: 27179440

Group type: EXPERIMENTAL
Intervention: 4-0 Vicryl
Number of subjects: 871

Group type: COMPARATOR
Intervention: 4-0 Monocryl
Number of subjects: 871
Study: 24112944

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for BRVO
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for CRVO
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus scatter photocoagulation for BRVO and CRVO
Number of subjects: 66
Study: 22203758

Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with standard oncology care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study: 20531012

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 2971

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 2971
Study: 18185135

Group type: EXPERIMENTAL
Intervention: Clinician grading of diabetic retinopathy severity
Number of subjects: 118

Group type: COMPARATOR
Intervention: Reading center (RC) grading of diabetic retinopathy severity
Number of subjects: 118
Study: 15906123

Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 12508388

Group type: EXPERIMENTAL
Intervention: IV doxycycline 300 mg/day for 14 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10533691

Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning and home follow-up by an advanced practice nurse (APN) for 4 weeks after discharge
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study: 8952749

Group type: EXPERIMENTAL
Intervention: Strategies for prevention and treatment of bone loss in lupus patients; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevention of steroid-induced bone loss; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of gonadal effects of cytotoxic agents; specific interventions not detailed.
Number of subjects: 0
Study: 1951568

Group type: EXPERIMENTAL
Intervention: Sadovsky fetal movement counting (n = 63)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cardiff fetal movement counting (n = 62)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 213
Study: 7009424

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time (during study period)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time (during outpatient period)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 30869820

Group type: EXPERIMENTAL
Intervention: Behavioral therapy with a written checklist (Group II)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Medical treatment with a written checklist (Group IV)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Medical treatment plus behavioral therapy without a checklist (Group III)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Behavioral therapy as a written guideline (Group I)
Number of subjects: 155
Study: 28003539

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily from 18-22 weeks of gestation to delivery)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 24985364

Group type: EXPERIMENTAL
Intervention: Pain diary group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 24037492

Group type: COMPARATOR
Intervention: TLSO (closed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TLSO (open)
Number of subjects: 20
Study: 22926666

Group type: EXPERIMENTAL
Intervention: Weight change (loss or gain) over 4 years
Number of subjects: 1826

Group type: COMPARATOR
Intervention: Stable weight (weight change < 5 lb)
Number of subjects: 1826

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²)
Number of subjects: 1826
Study: 19954716

Group type: EXPERIMENTAL
Intervention: Gliclazide/metformin combination tablet (80/500 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Co-administration of gliclazide (80 mg) and metformin (500 mg) as individual tablets
Number of subjects: 32
Study: 17355215

Group type: EXPERIMENTAL
Intervention: Novel compounds under investigation for heart failure treatment
Number of subjects: 0
Study: 15825717

Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 10% phenylephrine
Number of subjects: 564

Group type: COMPARATOR
Intervention: 1% tropicamide and 2.5% phenylephrine
Number of subjects: 564
Study: 15388907

Group type: EXPERIMENTAL
Intervention: Crude bullrout venom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocitoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative controls (pooled nonalgesic proteins)
Number of subjects: 0
Study: 10490152

Group type: EXPERIMENTAL
Intervention: Procaine with 0.3 mg epinephrine (EPI group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Procaine with 0.3 ml NaCl 0.9% (SALINE group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI group)
Number of subjects: 62
Study: 8944409

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg with fluvoxamine (mean dose 127 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1742482

Group type: EXPERIMENTAL
Intervention: GM-CSF (1.0 microgram/kg/d, increased to 3.0, 5.0, and 10.0 micrograms/kg as needed)
Number of subjects: 17

Group type: COMPARATOR
Intervention: GM-CSF (1.0 microgram/kg/d, increased as needed) with full-dose zidovudine (1,200 mg/d)
Number of subjects: 17
Study: 6896183

Group type: EXPERIMENTAL
Intervention: Tolamolol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tolamolol 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol 160 mg
Number of subjects: 6
Study: 31198999

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccination (23vPPV)
Number of subjects: 227

Group type: COMPARATOR
Intervention: No 23vPPV
Number of subjects: 227
Study: 31656454

Group type: EXPERIMENTAL
Intervention: Japanese soy sauce (Koikuchi Shoyu) exposure group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Phenylethyl alcohol (PEA) exposure group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water exposure group
Number of subjects: 72
Study: 30184451

Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy
Number of subjects: 1030
Study: 26477496

Group type: EXPERIMENTAL
Intervention: 5 or 10 mg daily ulipristal acetate for four repeated 12‐week treatment courses
Number of subjects: 451
Study: 24249538

Group type: COMPARATOR
Intervention: Chest radiography follow-up
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CT scan follow-up
Number of subjects: 500

Group type: COMPARATOR
Intervention: 6-monthly follow-up
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 3-monthly follow-up
Number of subjects: 500
Study: 23196436

Group type: COMPARATOR
Intervention: Azathioprine (AZP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 142
Study: 20718807

Group type: EXPERIMENTAL
Intervention: Fast protocol (increment: 2 w/6 s)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Slow protocol (increment: 1 w/6 s)
Number of subjects: 17
Study: 17570469

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study: 16014264

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12010339

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9885303

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin potassium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study: 8580277

Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension (200 mg loading dose followed by 100 mg q.d.s. for 2 weeks after symptom resolution)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension
Number of subjects: 42
Study: 30967395

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Rituximab with mycophenolate mofetil
Number of subjects: 254
Study: 29747616

Group type: COMPARATOR
Intervention: RBP4 tertiles (highest vs lowest)
Number of subjects: 167

Group type: COMPARATOR
Intervention: TTR tertiles (highest vs lowest)
Number of subjects: 167

Group type: COMPARATOR
Intervention: HOMA-IR tertiles (highest vs lowest)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TTR levels
Number of subjects: 167
Study: 27529806

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Poetry
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 24742965

Group type: EXPERIMENTAL
Intervention: S-PC (Smoker Patient Control) tool
Number of subjects: 229

Group type: COMPARATOR
Intervention: No S-PC tool
Number of subjects: 229
Study: 22640531

Group type: EXPERIMENTAL
Intervention: Care pathway intervention including formative evaluation, evidence-based key interventions, and support for implementation.
Number of subjects: 437

Group type: COMPARATOR
Intervention: Usual care (control arm).
Number of subjects: 437
Study: 19292590

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: efavirenz-based triple combination therapy
Number of subjects: 0
Study: 17383296

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in ischemic cardiomyopathy
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in nonischemic cardiomyopathy
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in patients with implantable cardioverter defibrillator (ICD)
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in non-ICD patients
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in New York Heart Association II patients
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Statin use in New York Heart Association III patients
Number of subjects: 2521
Study: 15486391

Group type: EXPERIMENTAL
Intervention: Pediatric collection tubes filled 100%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pediatric collection tubes filled 50%
Number of subjects: 30
Study: 11239184

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 624
Study: 11301568

Group type: EXPERIMENTAL
Intervention: Vitamin B complex capsules (fursulthiamine 50 mg, hydroxocobalamin 250 micrograms, pyridoxal phosphate 30 mg, and riboflavin 5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7870400

Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both experimental groups (verbal and written)
Number of subjects: 0
Study: 3360270

Group type: EXPERIMENTAL
Intervention: Paracentesis plus intravenous albumin infusion (40 g after each tap)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Paracentesis without intravenous albumin infusion
Number of subjects: 105
Study: 31599692

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein (HDL) cholesterol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cytokines
Number of subjects: 90
Study: 30049221

Group type: EXPERIMENTAL
Intervention: Transference Interpretation (TI)
Number of subjects: 2
Study: 29132458

Group type: EXPERIMENTAL
Intervention: remifentanil+midazolam
Number of subjects: 80

Group type: COMPARATOR
Intervention: midazolam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 80
Study: 26331821

Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 150 mg every 12 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 200 mg every 12 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride 125 mg every 8 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride (various doses)
Number of subjects: 30
Study: 23680830

Group type: EXPERIMENTAL
Intervention: Coflex interlaminar stabilization
Number of subjects: 322

Group type: COMPARATOR
Intervention: Posterolateral spinal fusion with spinal instrumentation
Number of subjects: 322
Study: 21959663

Group type: EXPERIMENTAL
Intervention: Anterior positioning splint therapy (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical therapy (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical therapy in addition to splint therapy (group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between group I and group II
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between group II and group III
Number of subjects: 60

Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 60
Study: 18303526

Group type: EXPERIMENTAL
Intervention: Loop diuretics, nitrates, inotropes (dobutamine, milrinone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nesiritide, Tolvaptan, Levosimedan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasoactive drugs
Number of subjects: 0
Study: 15902179

Group type: EXPERIMENTAL
Intervention: Coached pushing
Number of subjects: 128

Group type: COMPARATOR
Intervention: Uncoached pushing
Number of subjects: 128
Study: 12840625

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC; N = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Concentric exercise (CON; N = 6)
Number of subjects: 13
Study: 10488604

Group type: EXPERIMENTAL
Intervention: Venous puncture (P group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Alcohol swab friction (F group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 8829938

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nalbuphine
Number of subjects: 64
Study: 2052631

Group type: EXPERIMENTAL
Intervention: Acu‐ES group (electrical stimulation applied to four antihypertensive acupuncture points)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham‐ES group (electrical stimulation applied to non‐acupuncture‐point areas)
Number of subjects: 10
Study: 6315775

Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate-receptor antagonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31103481

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130
Study: 29575717

Group type: EXPERIMENTAL
Intervention: Antifungal therapy (terbinafine, fluconazole, itraconazole, voriconazole, or posaconazole) for 4 to >12 weeks with standard bronchodilator and anti-inflammatory agents
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Antifungal therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard therapy without antifungals
Number of subjects: 41
Study: 26223423

Group type: COMPARATOR
Intervention: SLActive Bone level implant (Institut Straumann AG, Basel, Switzerland)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CMI IS‐II active implant (Neobiotech Co., Seoul, Korea)
Number of subjects: 30
Study: 23657668

Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance (MRA) with minimal coverage of teeth and palate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mandibular repositioning appliance (MRA) with greater acrylic resin bulk and interocclusal contact
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both MRAs
Number of subjects: 24
Study: 22764291

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: artesunate plus amodiaquine (AS+AQ)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 780
Study: 20614571

Group type: EXPERIMENTAL
Intervention: HES 200 (6% hydroxyethyl starch 200/0.5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HES 130 (6% hydroxyethyl starch 130/0.4)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers)
Number of subjects: 35
Study: 17602086

Group type: EXPERIMENTAL
Intervention: gemcitabine 1,000 mg/m2 (days 1 and 8; every 21 days)
Number of subjects: 195

Group type: COMPARATOR
Intervention: PLD 50 mg/m2 (day 1; every 28 days)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 195

Group type: COMPARATOR
Intervention: PLD
Number of subjects: 195
Study: 14996349

Group type: EXPERIMENTAL
Intervention: Lamivudine prophylaxis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no lamivudine therapy)
Number of subjects: 18
Study: 11831309

Group type: EXPERIMENTAL
Intervention: Z100 and Scotchbond Multi‐Purpose (SBMP) restorative system
Number of subjects: 726
Study: 9509971

Group type: EXPERIMENTAL
Intervention: G‐CSF started on day 0
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: G‐CSF started on day +3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: G‐CSF started on day +5
Number of subjects: 70
Study: 7800170

Group type: EXPERIMENTAL
Intervention: 150 mg perazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unmedicated
Number of subjects: 20